We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 363

Supreme Court Will Judge Biosimilar Patent Dance
  • Foley & Lardner LLP
  • USA
  • January 16 2017

The U.S. Supreme Court has agreed to review some of the patent dispute resolution provisions of the Biologics Price Competition and Innovation Act


PTAB Holds Oral Hearings In Tecfidera Patent IPR and Interference
  • Foley & Lardner LLP
  • USA
  • December 6 2016

On November 30, 2016, the USPTO Patent Trial and Appeal Board (PTAB) held oral hearings in two different inter partes proceedings involving the


Federal Circuit Questions Standing For IPR Appeals
  • Foley & Lardner LLP
  • USA
  • January 11 2017

As I have written previously, neither the statutes nor the regulations governing Inter Partes Review (IPR) require the party challenging the patent


The PRICED Act Would Expedite Biosimilar Market Entry
  • Foley & Lardner LLP
  • USA
  • July 12 2016

Although the 12-year exclusivity period for original biologic products was a heavily negotiated provision of the Biologics Price Competition and


Federal Circuit finds Apotex ANDAs do not infringe Lysteda patents
  • Foley & Lardner LLP
  • USA
  • September 2 2014

In two decisions issued under the same name (Ferring B.V. V. Watson Laboratories, Inc.), the Federal Circuit upheld the validity of the Orange


Federal Circuit upholds one claim covering Combigan
  • Foley & Lardner LLP
  • USA
  • May 7 2013

In Allergan, Inc. v. Sandoz, Inc., the Federal Circuit reversed the district court in part, finding that Allergan's composition claims and most of


Swearing Behind A Reference With Reasonably Continuous Diligence
  • Foley & Lardner LLP
  • USA
  • November 16 2016

In Perfect Surgical Techniques, Inc. v. Olympus America, Inc., the Federal Circuit vacated and remanded a USPTO Patent Trial and Appeal Board


Federal Circuit finds hole in “this” priority claim
  • Foley & Lardner LLP
  • USA
  • January 29 2014

In Medtronic CoreValve, LLC v. Edwards Lifesciences Corp., the Federal Circuit affirmed the district court's finding that the patent at issue was


District court finds Genetic Technologies patent invalid under 101 on motion to dismiss
  • Foley & Lardner LLP
  • USA
  • November 6 2014

Judge Stark of the U.S. District Court for the District of Delaware granted defendants' motion to dismiss Genetic Technologies, Ltd.'s patent


Federal Circuit invalidates Myriad primer and method claims as lacking subject matter eligibility
  • Foley & Lardner LLP
  • USA
  • December 17 2014

In a case styled as In re BRCA1- and BRCA2-Based Hereditary Cancer Test Patent Litigation (also known as Myriad v. Ambry), the Federal Circuit held